Premium
Clinical and Biochemical Effects of Calcium‐Hopantenate on Neuroleptics‐Induced Tardive Dyskinesia
Author(s) -
Kashihara Kenichi,
Ebara Takashi,
Yamamoto Mitsutoshi,
Ogawa Toshihiko,
Harada Toshiki,
Otsuki Saburo
Publication year - 1985
Publication title -
psychiatry and clinical neurosciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.609
H-Index - 74
eISSN - 1440-1819
pISSN - 1323-1316
DOI - 10.1111/j.1440-1819.1985.tb02898.x
Subject(s) - tardive dyskinesia , dyskinesia , medicine , calcium , pharmacology , psychology , neuroscience , schizophrenia (object oriented programming) , psychiatry , parkinson's disease , disease
Calcium‐hopantenate (HOP A), a derivative of GABA, was administered to 9 psychiatric patients with neuroleptics‐induced tardive dyskinesia. In a clinical study, involuntary movements have improved significantly after a 4–8‐week medication. Although there was no correlation between the cerebrospinal fluid (CSF) levels of HOPA, GABA, HVA or clinical response, the CSF HOPA levels significantly correlated with changes in the CSF GABA levels. These results suggest that HOPA alleviates the symptoms of tardive dyskinesia being mediated by the central GABAergic mechanisms.